A new CTLA-4 drug is turning heads in hard-to-treat lung cancer
For patients with advanced squamous lung cancer who've already tried immunotherapy, options have been slim for a decade — but that may be changing. Updated data from the PRESERVE-003 trial show that gotistobart, a next-generation CTLA-4 antibody, nearly doubled median overall survival compared to standard chemotherapy. Experts are cautiously optimistic, though they stress the need for proactive toxicity management and broader genomic testing.
Explore all the latest healthcare news and insights